礼来的替尔泊肽在国内报上市今日,CDE 官网显示,替尔泊肽新适应症在国内报上市。这是礼来在中国递交的第 4 项上市申请。替尔泊肽注射液(Tirzepatide)是首款治疗 2 型糖尿病的 GLP-1R /GIPR 双靶点降糖药,每周一次给药,曾在大型 III 期临床中头对头击败司美格鲁肽,引发热议。在美国,于 2022 年 5 月获批上市用于治疗 2 型糖尿病(T2DM),去年年底又获批减重适应症...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.